文献速递肝病消化内镜

内镜超声引导下门体压力梯度与临床参数及肝脏组织学相关

Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient Correlates With Clinical Parameters and Liver Histology.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-01-30

这项多中心回顾性研究纳入2020年1月至2022年12月接受内镜超声引导下门体压力梯度(EUS-PPG)测量的385例患者,技术成功率为97%。EUS-PPG与门静脉高压临床参数及肝组织学相关,EUS-PPG >5 mm Hg是肝硬化的最强预测因子,优于无创纤维化标志物。

要点

  • EUS-PPG技术成功率为97%,仅发生2例轻微不良事件(术后疼痛)。
  • 有食管静脉曲张、门静脉高压性胃病或血小板减少者的门体压力梯度中位数更高。
  • EUS-PPG >5 mm Hg是肝硬化的最强预测因子,优于Fibrosis-4和APRI。

核心结论

  • EUS-PPG测量在技术上可行且安全,与门静脉高压临床参数及肝脏组织学强相关。
  • 肝硬化的最强预测因子是EUS-PPG >5 mm Hg,优于无创纤维化标志物。

研究设计与样本

  • 多中心、回顾性研究,纳入2020年1月至2022年12月因疑似肝病或门静脉高压接受EUS-PPG的患者。
  • 8个中心共纳入385例患者,373例成功完成EUS-PPG(技术成功率97%)。

主要发现

  • 有食管静脉曲张者门体压力梯度中位数为11.6 mm Hg,无食管静脉曲张者为4.1 mm Hg(P < .001)。
  • 有门静脉高压性胃病者门体压力梯度中位数为10.5 mm Hg,无门静脉高压性胃病者为3.3 mm Hg(P < .001)。
  • 有血小板减少者门体压力梯度中位数为7.6 mm Hg,无血小板减少者为4.4 mm Hg(P < .001)。
  • 有门静脉高压者组织学肝硬化的可能性是无门静脉高压者的6.7倍,有临床显著门静脉高压(PPG ≥10)者组织学肝硬化的可能性是无临床显著门静脉高压者的3.8倍。
  • EUS-PPG预测活检证实的肝硬化的曲线下面积为0.84,优于Fibrosis-4的0.72和APRI的0.54。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Endoscopic ultrasound-guided portosystemic pressure gradient measurement (EUS-PPG) is a novel technique to evaluate for portal hypertension (PH), a diagnosis that can prognosticate and guide therapy for patients. This study evaluated the safety and efficacy of EUS-PPG and correlation with clinical parameters and liver histology. METHODS: We conducted a multicenter, retrospective study of patients undergoing EUS-PPG from January 2020 to December 2022 for suspected liver disease or PH. Linear regression was used to examine the relationship between EUS-PPG and clinical parameters of PH, and the chi-square test, Fisher's exact test, and Wilcoxon rank sum test described correlation with liver biopsy histology and noninvasive markers of fibrosis (Fibrosis-4, APRI [aspartate aminotransferase-to-platelet ratio index]). Logistic regression was performed to identify the strongest predictor of histologic cirrhosis. RESULTS: Across 8 centers, 385 patients were enrolled and 373 had successful EUS-PPG (technical success 97%). Higher median PPGs were observed in patients with than without esophageal varices (11.6 mm Hg vs 4.1 mm Hg), portal hypertensive gastropathy (10.5 mm Hg vs 3.3 mm Hg), and thrombocytopenia (7.6 mm Hg vs 4.4 mm Hg) (P < .001). Individuals with PH and clinically significant PH (PPG ≥10) were 6.7 and 3.8 times more likely to have cirrhosis on histology, respectively. EUS-PPG was the best overall predictor of biopsy-proven cirrhosis (area under the curve 0.84) compared with Fibrosis-4 (0.72), and APRI (0.54). There were 2 minor adverse events related to PPG (postprocedural pain). CONCLUSIONS: EUS-PPG measurement was technically feasible and safe and demonstrated a strong correlation with clinical parameters of PH and liver histology. The strongest predictor of cirrhosis was EUS-PPG >5 mm Hg, which outperformed noninvasive markers of fibrosis.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Kolb JM, Monachese M, Rubin RA, et al. Endoscopic Ultrasound-Guided Portosystemic Pressure Gradient Correlates With Clinical Parameters and Liver Histology. Clin Gastroenterol Hepatol. 2025. PMID: 39892628. doi:10.1016/j.cgh.2024.12.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。